2025-524310-28-00CompletedPhase 1
A Study Evaluating the Safety and Tolerability of a Novel Formulation of QRL-101 in Healthy Participants
Source: EU CTIS (euclinicaltrials.eu) · Last updated 23 Jan 2026
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- First submitted
- 24 Nov 2025
- Start date
- 2 Feb 2026
- Lead sponsor
- Quralis Corp.
- EU CT number
- 2025-524310-28-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 48
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pharmaceutical Research Associates Group B.V. | Groningen | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.